The Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca UK Limited) in combination with gemcitabine and cisplatin for adult patients with locally advanced or metastatic biliary tract cancer (BTC). More information. 

The attached document provides a summary of key results from the TOPAZ-1 trial, along with other important information about the use of IMFINZI in patients with advanced BTCs.